Skip to content
ETopical – Lifestyle
Author:
Transgene S.A.
Availability of Transgene’s 2025 Universal Registration Document (URD)
April 9, 2026
Transgene to Participate in Upcoming Investor Meetings
April 7, 2026
Transgene and NEC Bio Sign License Agreement to Prepare the Next Steps of the Development of TG4050 in Head and Neck Cancer
April 2, 2026
Transgene Continues Progress to Reshape Early-Stage Cancer Treatment through Individualized Neoantigen Therapeutic Vaccines (INTV) Backed by Financial Visibility Until Early 2028
March 24, 2026
←
Previous Page
1
2